143 results on '"Sommerstein, R."'
Search Results
2. Impact of an infection control service in a university psychiatric hospital: significantly lowering healthcare-associated infections during 18 years of surveillance
- Author
-
Büchler, A.C., Sommerstein, R., Dangel, M., Tschudin-Sutter, S., Vogel, M., and Widmer, A.F.
- Published
- 2020
- Full Text
- View/download PDF
3. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass
- Author
-
Baddour, L.M., Diekema, D., Fernández-Hidalgo, N., Gordon, S., Hasse, B., Lundgren, J., Manfrin, V., Nomura, J., Scriven, J., Stewart, R., Wagner, D., Tang, T.H.-C., Herwaldt, L.A., Mertz, D., Sax, H., Schreiber, P., Sommerstein, R., Stewardson, A., Whitener, C.J., Widmer, A., Brown Elliot, B.A., Daley, C., Freiberger, T., van Ingen, J., Keller, P., Kohl, T.A., Maurer, F., Niemann, S., Wallace, R.J., Jr., Falk, V., Halbe, M., Mestres, C.A., Zweifel, S., Bettex, D., Hernandez Conte, A., Chand, M., Jarashow, M.C., Lamagni, T., Plachouras, D., Perkins, K.M., Hannan, M.M., Keller, P.M., Maurer, F.P., Durante-Mangoni, E., Stuart, R.L., Schreiber, P.W., Daley, C.L., Stewardson, A.J., Perkins, K., Sander, P., Schulthess, B., Scriven, J.E., Brown-Elliott, B.A., Miro, J.M., Hoen, B., Athan, E., Bayer, A., Barsic, B., Corey, G.R., Chu, V.H., Durack, D.T., Fortes, C.Q., Fowler, V., Krachmer, A.W., Durante-Magnoni, E., and Wilson, W.R.
- Published
- 2020
- Full Text
- View/download PDF
4. Characterizing non-linear effects of hospitalisation duration on antimicrobial resistance in respiratory isolates: an analysis of a prospective nationwide surveillance system
- Author
-
Burnens, A., Cherkaoui, A., Dubuis, O., Egli, A., Gaia, V., Koch, D., Kronenberg, A., Leib, S.L., Luyet, S., Nordmann, P., Perreten, V., Piffaretti, J.-C., Prod’hom, G., Schrenzel, J., Widmer, A.F., Zanetti, G., Zbinden, R., Sommerstein, R., Atkinson, A., Lo Priore, E.F., and Marschall, J.
- Published
- 2018
- Full Text
- View/download PDF
5. Implementation of minimum structural requirements for infection prevention through digitalization
- Author
-
Leiblein, T.W., primary, Gligor, M., additional, Egloff, F., additional, Seger, E., additional, Scheiber, K., additional, and Sommerstein, R., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Factors associated with methicillin-resistant coagulase-negative staphylococci as causing organisms in deep sternal wound infections after cardiac surgery
- Author
-
Sommerstein, R., Kohler, P., Wilhelm, M.J., Kuster, S.P., and Sax, H.
- Published
- 2015
- Full Text
- View/download PDF
7. Proposal for an updated taxonomy for isolation precautions in healthcare facilities: the term ‘droposol’
- Author
-
Widmer, A.F., Conly, J., and Sommerstein, R.
- Published
- 2025
- Full Text
- View/download PDF
8. Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors
- Author
-
Sahin, M., Remy, M.M., Fallet, B., Sommerstein, R., Florova, M., Langner, A., Klausz, K., Straub, T., Kreutzfeldt, M., Wagner, I., Schmidt, C.T., Malinge, P., Magistrelli, G., Izui, S., Pircher, H., Verbeek, J.S., Merkler, D., Peipp, M., and Pinschewer, D.D.
- Abstract
Across the animal kingdom, multivalency discriminates antibodies from all other immunoglobulin superfamily members. The evolutionary forces conserving multivalency above other structural hallmarks of antibodies remain, however, incompletely defined.Here, we engineer monovalent either Fc-competent or -deficient antibody formats to investigate mechanisms of protection of neutralizing antibodies (nAbs) and non-neutralizing antibodies (nnAbs) in virus-infected mice. Antibody bivalency enables the tethering of virions to the infected cell surface, inhibits the release of virions in cell culture, and suppresses viral loads in vivo independently of Fc gamma receptor (Fc gamma R) interactions. In return, monovalent antibody formats either do not inhibit virion release and fail to protect in vivo or their protective efficacy is largely Fc gamma R dependent. Protection in mice correlates with virus-release-inhibiting activity of nAb and nnAb rather than with their neutralizing capacity.These observations provide mechanistic insights into the evolutionary conservation of antibody bivalency and help refining correlates of nnAb protection for vaccine development.
- Published
- 2022
- Full Text
- View/download PDF
9. Fatal Neisseria sicca endocarditis
- Author
-
Sommerstein, R., Ramsay, D., Dubuis, O., Waser, S., Aebersold, F., and Vogt, M.
- Published
- 2013
- Full Text
- View/download PDF
10. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass
- Author
-
Hasse, B., primary, Hannan, M.M., additional, Keller, P.M., additional, Maurer, F.P., additional, Sommerstein, R., additional, Mertz, D., additional, Wagner, D., additional, Fernández-Hidalgo, N., additional, Nomura, J., additional, Manfrin, V., additional, Bettex, D., additional, Hernandez Conte, A., additional, Durante-Mangoni, E., additional, Tang, T.H.-C., additional, Stuart, R.L., additional, Lundgren, J., additional, Gordon, S., additional, Jarashow, M.C., additional, Schreiber, P.W., additional, Niemann, S., additional, Kohl, T.A., additional, Daley, C.L., additional, Stewardson, A.J., additional, Whitener, C.J., additional, Perkins, K., additional, Plachouras, D., additional, Lamagni, T., additional, Chand, M., additional, Freiberger, T., additional, Zweifel, S., additional, Sander, P., additional, Schulthess, B., additional, Scriven, J.E., additional, Sax, H., additional, van Ingen, J., additional, Mestres, C.A., additional, Diekema, D., additional, Brown-Elliott, B.A., additional, Wallace, R.J., additional, Baddour, L.M., additional, Miro, J.M., additional, Hoen, B., additional, Athan, E., additional, Bayer, A., additional, Barsic, B., additional, Corey, G.R., additional, Chu, V.H., additional, Durack, D.T., additional, Fortes, C.Q., additional, Fowler, V., additional, Krachmer, A.W., additional, Durante-Magnoni, E., additional, Wilson, W.R., additional, Hasse, B., additional, Scriven, J., additional, Stewart, R., additional, Herwaldt, L.A., additional, Schreiber, P., additional, Stewardson, A., additional, Widmer, A., additional, Brown Elliot, B.A., additional, Daley, C., additional, Keller, P., additional, Maurer, F., additional, Falk, V., additional, Halbe, M., additional, and Perkins, K.M., additional
- Published
- 2020
- Full Text
- View/download PDF
11. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case–crossover study
- Author
-
Hauser, T, Mahr, A, Metzler, C, Coste, J, Sommerstein, R, Gross, W L, Guillevin, L, and Hellmich, B
- Published
- 2008
- Full Text
- View/download PDF
12. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass
- Author
-
Hasse, B., Hannan, M.M., Keller, P.M., Maurer, F.P., Sommerstein, R., Mertz, D., Ingen, J. van, Halbe, M., Perkins, K.M., Hasse, B., Hannan, M.M., Keller, P.M., Maurer, F.P., Sommerstein, R., Mertz, D., Ingen, J. van, Halbe, M., and Perkins, K.M.
- Abstract
Contains fulltext : 216662.pdf (Publisher’s version ) (Open Access)
- Published
- 2020
13. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass.
- Author
-
Sander P., Chu V.H., Durack D.T., Fortes C.Q., Fowler V., Krachmer A.W., Wilson W.R., Stewart R., Herwaldt L.A., Widmer A., Brown Elliot B.A., Falk V., Halbe M., Scriven J.E., Sax H., van Ingen J., Mestres C.A., Diekema D., Brown-Elliott B.A., Wallace R.J., Baddour L.M., Miro J.M., Hoen B., Athan E., Bayer A., Barsic B., Stuart R.L., Hasse B., Hannan M.M., Keller P.M., Maurer F.P., Sommerstein R., Mertz D., Wagner D., Fernandez-Hidalgo N., Nomura J., Manfrin V., Bettex D., Hernandez Conte A., Durante-Mangoni E., Tang T.H.-C., Lundgren J., Gordon S., Jarashow M.C., Schreiber P.W., Niemann S., Kohl T.A., Daley C.L., Stewardson A.J., Whitener C.J., Perkins K., Plachouras D., Lamagni T., Chand M., Freiberger T., Zweifel S., Corey G.R., Schulthess B., Sander P., Chu V.H., Durack D.T., Fortes C.Q., Fowler V., Krachmer A.W., Wilson W.R., Stewart R., Herwaldt L.A., Widmer A., Brown Elliot B.A., Falk V., Halbe M., Scriven J.E., Sax H., van Ingen J., Mestres C.A., Diekema D., Brown-Elliott B.A., Wallace R.J., Baddour L.M., Miro J.M., Hoen B., Athan E., Bayer A., Barsic B., Stuart R.L., Hasse B., Hannan M.M., Keller P.M., Maurer F.P., Sommerstein R., Mertz D., Wagner D., Fernandez-Hidalgo N., Nomura J., Manfrin V., Bettex D., Hernandez Conte A., Durante-Mangoni E., Tang T.H.-C., Lundgren J., Gordon S., Jarashow M.C., Schreiber P.W., Niemann S., Kohl T.A., Daley C.L., Stewardson A.J., Whitener C.J., Perkins K., Plachouras D., Lamagni T., Chand M., Freiberger T., Zweifel S., Corey G.R., and Schulthess B.
- Abstract
Mycobacterial infection-related morbidity and mortality in patients following cardiopulmonary bypass surgery is high and there is a growing need for a consensus-based expert opinion to provide international guidance for diagnosing, preventing and treating in these patients. In this document the International Society for Cardiovascular Infectious Diseases (ISCVID) covers aspects of prevention (field of hospital epidemiology), clinical management (infectious disease specialists, cardiac surgeons, ophthalmologists, others), laboratory diagnostics (microbiologists, molecular diagnostics), device management (perfusionists, cardiac surgeons) and public health aspects.Copyright © 2019 The Author(s)
- Published
- 2020
14. International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass
- Author
-
Hasse, B, Hannan, MM, Keller, PM, Maurer, FP, Sommerstein, R, Mertz, D, Wagner, D, Fernandez-Hidalgo, N, Nomura, J, Manfrin, V, Bettex, D, Conte, AH, Durante-Mangoni, E, Tang, TH-C, Stuart, RL, Lundgren, J, Gordon, S, Jarashow, MC, Schreiber, PW, Niemann, S, Kohl, TA, Daley, CL, Stewardson, AJ, Whitener, CJ, Perkins, K, Plachouras, D, Lamagni, T, Chand, M, Freiberger, T, Zweifel, S, Sander, P, Schulthess, B, Scriven, JE, Sax, H, van Ingen, J, Mestres, CA, Diekema, D, Brown-Elliott, BA, Wallace, RJ, Baddour, LM, Miro, JM, Hoen, B, Athan, E, Bayer, A, Barsic, B, Corey, GR, Chu, VH, Durack, DT, Querido Fortes, C, Fowler, V, Krachmer, AW, Durante-Magnoni, E, Miro, M, Wilson, WR, Striven, J, Stewart, R, Herwaldt, LA, Schreiber, P, Stewardson, A, Widmer, A, Elliot, BAB, Daley, C, Keller, P, Maurer, F, Falk, V, Halbe, M, Perkins, KM, Hasse, B, Hannan, MM, Keller, PM, Maurer, FP, Sommerstein, R, Mertz, D, Wagner, D, Fernandez-Hidalgo, N, Nomura, J, Manfrin, V, Bettex, D, Conte, AH, Durante-Mangoni, E, Tang, TH-C, Stuart, RL, Lundgren, J, Gordon, S, Jarashow, MC, Schreiber, PW, Niemann, S, Kohl, TA, Daley, CL, Stewardson, AJ, Whitener, CJ, Perkins, K, Plachouras, D, Lamagni, T, Chand, M, Freiberger, T, Zweifel, S, Sander, P, Schulthess, B, Scriven, JE, Sax, H, van Ingen, J, Mestres, CA, Diekema, D, Brown-Elliott, BA, Wallace, RJ, Baddour, LM, Miro, JM, Hoen, B, Athan, E, Bayer, A, Barsic, B, Corey, GR, Chu, VH, Durack, DT, Querido Fortes, C, Fowler, V, Krachmer, AW, Durante-Magnoni, E, Miro, M, Wilson, WR, Striven, J, Stewart, R, Herwaldt, LA, Schreiber, P, Stewardson, A, Widmer, A, Elliot, BAB, Daley, C, Keller, P, Maurer, F, Falk, V, Halbe, M, and Perkins, KM
- Abstract
Mycobacterial infection-related morbidity and mortality in patients following cardiopulmonary bypass surgery is high and there is a growing need for a consensus-based expert opinion to provide international guidance for diagnosing, preventing and treating in these patients. In this document the International Society for Cardiovascular Infectious Diseases (ISCVID) covers aspects of prevention (field of hospital epidemiology), clinical management (infectious disease specialists, cardiac surgeons, ophthalmologists, others), laboratory diagnostics (microbiologists, molecular diagnostics), device management (perfusionists, cardiac surgeons) and public health aspects.
- Published
- 2020
15. Reemergence of Mycobacterium chimaera in Heater-Cooler Units despite Intensified Cleaning and Disinfection Protocol
- Author
-
Schreiber PW, Kuster SP, Hasse B, Bayard C, Ruegg C, Kohler P, Keller PM, Bloemberg GV, Maisano F, Bettex D, Halbe M, Sommerstein R, Sax H, Schreiber, Pw, Kuster, Sp, Hasse, B, Bayard, C, Ruegg, C, Kohler, P, Keller, Pm, Bloemberg, Gv, Maisano, F, Bettex, D, Halbe, M, Sommerstein, R, and Sax, H
- Published
- 2016
16. Fatal Neisseria sicca endocarditis
- Author
-
Sommerstein, R., Ramsay, D., Dubuis, O., Waser, S., Aebersold, F., Vogt, M., Sommerstein, R., Ramsay, D., Dubuis, O., Waser, S., Aebersold, F., and Vogt, M.
- Published
- 2018
17. Characterizing non-linear effects of hospitalisation duration on antimicrobial resistance in respiratory isolates: an analysis of a prospective nationwide surveillance system
- Author
-
Sommerstein, R., primary, Atkinson, A., additional, Lo Priore, E.F., additional, Kronenberg, A., additional, Marschall, J., additional, Burnens, A., additional, Cherkaoui, A., additional, Dubuis, O., additional, Egli, A., additional, Gaia, V., additional, Koch, D., additional, Leib, S.L., additional, Luyet, S., additional, Nordmann, P., additional, Perreten, V., additional, Piffaretti, J.-C., additional, Prod’hom, G., additional, Schrenzel, J., additional, Widmer, A.F., additional, Zanetti, G., additional, and Zbinden, R., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Global Mycobacterium chimaera outbreak: challenges for the near future
- Author
-
Sommerstein, R., primary, Kohler, P.P., additional, and Hasse, B., additional
- Published
- 2017
- Full Text
- View/download PDF
19. Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study
- Author
-
Ingen, J. van, Kohl, T.A., Kranzer, K., Hasse, B., Keller, P.M., Szafranska, A.K., Hillemann, D., Chand, M., Schreiber, P.W., Sommerstein, R., Berger, C., Genoni, M., Ruegg, C., Troillet, N., Widmer, A.F., Becker, S.L., Herrmann, M., Eckmanns, T., Haller, S., Holler, C., Debast, S.B., Wolfhagen, M.J., Hopman, J., Kluytmans, J., Langelaar, M., Notermans, D.W., Oever, J. ten, Barselaar, P. van den, Vonk, A.B., Vos, M.C., Ahmed, N., Brown, T., Crook, D., Lamagni, T., Phin, N., Smith, E.G., Zambon, M., Serr, A., Gotting, T., Ebner, W., Thurmer, A., Utpatel, C., Sproer, C., Bunk, B., Nubel, U., Bloemberg, G.V., Bottger, E.C., Niemann, S., Wagner, D., Sax, H., Ingen, J. van, Kohl, T.A., Kranzer, K., Hasse, B., Keller, P.M., Szafranska, A.K., Hillemann, D., Chand, M., Schreiber, P.W., Sommerstein, R., Berger, C., Genoni, M., Ruegg, C., Troillet, N., Widmer, A.F., Becker, S.L., Herrmann, M., Eckmanns, T., Haller, S., Holler, C., Debast, S.B., Wolfhagen, M.J., Hopman, J., Kluytmans, J., Langelaar, M., Notermans, D.W., Oever, J. ten, Barselaar, P. van den, Vonk, A.B., Vos, M.C., Ahmed, N., Brown, T., Crook, D., Lamagni, T., Phin, N., Smith, E.G., Zambon, M., Serr, A., Gotting, T., Ebner, W., Thurmer, A., Utpatel, C., Sproer, C., Bunk, B., Nubel, U., Bloemberg, G.V., Bottger, E.C., Niemann, S., Wagner, D., and Sax, H.
- Abstract
Item does not contain fulltext, BACKGROUND: Since 2013, over 100 cases of Mycobacterium chimaera prosthetic valve endocarditis and disseminated disease were notified in Europe and the USA, linked to contaminated heater-cooler units (HCUs) used during cardiac surgery. We did a molecular epidemiological investigation to establish the source of these patients' disease. METHODS: We included 24 M chimaera isolates from 21 cardiac surgery-related patients in Switzerland, Germany, the Netherlands, and the UK, 218 M chimaera isolates from various types of HCUs in hospitals, from LivaNova (formerly Sorin; London, UK) and Maquet (Rastatt, Germany) brand HCU production sites, and unrelated environmental sources and patients, as well as eight Mycobacterium intracellulare isolates. Isolates were analysed by next-generation whole-genome sequencing using Illumina and Pacific Biosciences technologies, and compared with published M chimaera genomes. FINDINGS: Phylogenetic analysis based on whole-genome sequencing of 250 isolates revealed two major M chimaera groups. Cardiac surgery-related patient isolates were all classified into group 1, in which all, except one, formed a distinct subgroup. This subgroup also comprised isolates from 11 cardiac surgery-related patients reported from the USA, most isolates from LivaNova HCUs, and one from their production site. Isolates from other HCUs and unrelated patients were more widely distributed in the phylogenetic tree. INTERPRETATION: HCU contamination with M chimaera at the LivaNova factory seems a likely source for cardiothoracic surgery-related severe M chimaera infections diagnosed in Switzerland, Germany, the Netherlands, the UK, the USA, and Australia. Protective measures and heightened clinician awareness are essential to guarantee patient safety. FUNDING: Partly funded by the EU Horizon 2020 programme, its FP7 programme, the German Center for Infection Research (DZIF), the Swiss National Science Foundation, the Swiss Federal Office of Public Health, and National
- Published
- 2017
20. Cerebrospinal Fluid Findings in an Adult with Human Metapneumovirus-Associated Encephalitis
- Author
-
Jeannet, N, van den Hoogen, BG, Schefold, JC, Suter-Riniker, F, Sommerstein, R, Jeannet, N, van den Hoogen, BG, Schefold, JC, Suter-Riniker, F, and Sommerstein, R
- Published
- 2017
21. Cardiac surgery, nosocomial infection, and the built environment
- Author
-
Sommerstein, R., primary, Jenni, H., additional, Carrel, T., additional, and Marschall, J., additional
- Published
- 2016
- Full Text
- View/download PDF
22. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery.
- Author
-
Kohler, P., Kuster, S.P., Bloemberg, G., Schulthess, B., Frank, M., Tanner, F.C., Rössle, M., Böni, C., Falk, V., Wilhelm, M.J., Sommerstein, R., Achermann, Y., Oever, J. ten, Debast, S.B., Wolfhagen, M.J., Bruinsma, G.J. Brandon Bravo, Vos, M.C., Bogers, A., Serr, A., Beyersdorf, F., Sax, H., Böttger, E.C., Weber, R., Ingen, J. van, Wagner, D., Hasse, B., Kohler, P., Kuster, S.P., Bloemberg, G., Schulthess, B., Frank, M., Tanner, F.C., Rössle, M., Böni, C., Falk, V., Wilhelm, M.J., Sommerstein, R., Achermann, Y., Oever, J. ten, Debast, S.B., Wolfhagen, M.J., Bruinsma, G.J. Brandon Bravo, Vos, M.C., Bogers, A., Serr, A., Beyersdorf, F., Sax, H., Böttger, E.C., Weber, R., Ingen, J. van, Wagner, D., and Hasse, B.
- Abstract
Item does not contain fulltext
- Published
- 2015
23. Factors associated with methicillin-resistant coagulase-negative staphylococci as causing organisms in deep sternal wound infections after cardiac surgery
- Author
-
Sommerstein, R, Kohler, P, Wilhelm, M J, Kuster, S P, Sax, H, Sommerstein, R, Kohler, P, Wilhelm, M J, Kuster, S P, and Sax, H
- Abstract
Established preoperative antibiotic prophylaxis in cardiac surgery is ineffective against methicillin-resistant coagulase-negative staphylococci (CoNS). This case-control study aimed to determine factors predicting deep sternal wound infections due to methicillin-resistant CoNS. All cardiac surgery patients undergoing sternotomy between June 2009 and March 2013 prospectively documented in a Swiss tertiary care center were included. Among 1999 patients, 82 (4.1%) developed deep sternal wound infection. CoNS were causal in 36 (44%) patients, with 25/36 (69%) being methicillin resistant. Early reintervention for noninfectious causes (odds ratio (OR) 4.3; 95% confidence interval (CI) 1.9-9.5) was associated with methicillin-resistant CoNS deep sternal wound infection. Among CoNS deep sternal wound infection, perioperative antimicrobial therapy (p 0.002), early reintervention for noninfectious causes (OR 7.9; 95% CI 0.9-71.1) and time between surgery and diagnosis of infection over 21 days (OR 10.8; 95% CI 1.2-97.8) were associated with methicillin resistance. These findings may help to better tailor preoperative antimicrobial prophylaxis.
- Published
- 2015
24. Fatal Neisseria sicca endocarditis
- Author
-
Sommerstein, R, Ramsay, D, Dubuis, O, Waser, S, Aebersold, F, Vogt, M, Sommerstein, R, Ramsay, D, Dubuis, O, Waser, S, Aebersold, F, and Vogt, M
- Published
- 2013
25. Cerebral venous sinus thrombosis as a complication of a microendoscopic discectomy
- Author
-
Sommerstein, R, Jung, H H, Knoblauch, C, Sommerstein, R, Jung, H H, and Knoblauch, C
- Published
- 2011
26. Cerebral Venous Sinus Thrombosis as a Complication of a Microendoscopic Discectomy
- Author
-
Sommerstein, R., primary, Jung, H.H., additional, and Knoblauch, C., additional
- Published
- 2011
- Full Text
- View/download PDF
27. Interferon-driven deletion of antiviral B cells at the onset of chronic infection
- Author
-
Straub, Tobias, Geier, Florian, Zimmer, Gert, Merkler, Doron, Larimore, Kevin, Kreutzfeldt, Mario, Fallet, Benedict, Sommerstein, R., Page, Nicolas, Cornille, Karen, Greenberg, Philip D, Remy, Melissa, Ertuna, Yusuf I, Pircher, Hanspeter, Pinschewer, Daniel D, and Narr, Kerstin
- Subjects
630 Agriculture ,610 Medicine & health ,3. Good health - Abstract
Inadequate antibody responses and perturbed B cell compartments represent hallmarks of persistent microbial infections, but the mechanisms whereby persisting pathogens suppress humoral immunity remain poorly defined. Using adoptive transfer experiments in the context of a chronic lymphocytic choriomeningitis virus (LCMV) infection of mice, we have documented rapid depletion of virus-specific B cells that coincided with the early type I interferon response to infection. We found that the loss of activated B cells was driven by type I interferon (IFN-I) signaling to several cell types including dendritic cells, T cells and myeloid cells. Intriguingly, this process was independent of B cell-intrinsic IFN-I sensing and resulted from biased differentiation of naïve B cells into short-lived antibody-secreting cells. The ability to generate robust B cell responses was restored upon IFN-I receptor blockade or, partially, when experimentally depleting myeloid cells or the IFN-I-induced cytokines interleukin 10 and tumor necrosis factor alpha. We have termed this IFN-I-driven depletion of B cells "B cell decimation". Strategies to counter "B cell decimation" should thus help us better leverage humoral immunity in the combat against persistent microbial diseases.
28. Transmission of Mycobacterium chimaera from Heater-Cooler Units during Cardiac Surgery despite an Ultraclean Air Ventilation System
- Author
-
Sommerstein R, Rüegg C, Philipp Kohler, Bloemberg G, Sp, Kuster, and Sax H
29. Fatal Neisseria sicca endocarditis
- Author
-
Sommerstein, R., Ramsay, D., Dubuis, O., Waser, S., Aebersold, F., Vogt, M., Sommerstein, R., Ramsay, D., Dubuis, O., Waser, S., Aebersold, F., and Vogt, M.
30. Global Mycobacterium chimaera outbreak: challenges for the near future
- Author
-
Rami Sommerstein, Philipp Kohler, Barbara Hasse, University of Zurich, and Sommerstein, R
- Subjects
Microbiology (medical) ,Cross infection ,Veterinary medicine ,Air microbiology ,Air Microbiology ,610 Medicine & health ,030501 epidemiology ,Global Health ,2726 Microbiology (medical) ,Disease Outbreaks ,Mycobacterium ,10234 Clinic for Infectious Diseases ,03 medical and health sciences ,0302 clinical medicine ,Global health ,Humans ,Medicine ,Infection control ,030212 general & internal medicine ,Cardiac Surgical Procedures ,Aerosols ,Cross Infection ,Infection Control ,Mycobacterium Infections ,biology ,business.industry ,Outbreak ,General Medicine ,2725 Infectious Diseases ,biology.organism_classification ,Virology ,Infectious Diseases ,0305 other medical science ,business - Published
- 2017
31. Povidone Iodine vs Chlorhexidine Gluconate in Alcohol for Preoperative Skin Antisepsis-Reply.
- Author
-
Widmer AF, Sommerstein R, and Jent P
- Published
- 2025
- Full Text
- View/download PDF
32. In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
- Author
-
Grant R, de Kraker MEA, Buetti N, Jackson H, Abbas M, Sobel JA, Sommerstein R, Eder M, Balmelli C, Troillet N, Schreiber PW, Jent P, Senn L, Flury D, Tschudin-Sutter S, Buettcher M, Süveges M, Urbini L, Keiser O, Roder U, Harbarth S, and Zanella MC
- Abstract
Background: As COVID-19 is integrated into existing infectious disease control programs, it is important to understand the comparative clinical impact of COVID-19 and other respiratory diseases., Methods: We conducted a retrospective cohort study of patients with symptomatic healthcare-associated COVID-19 or influenza reported to the nationwide, hospital-based surveillance system in Switzerland. Included patients were adults (≥18 years) hospitalized for ≥3 days in tertiary care and large regional hospitals. Patients had COVID-19 symptoms and a RT-PCR-confirmed SARS-CoV-2 infection ≥3 days after hospital admission between 1 February 2022 and 30 April 2023, or influenza symptoms and a RT-PCR-confirmed influenza A or B infection ≥3 days after hospital admission between 1 November 2018 and 30 April 2023. Primary and secondary outcomes were 30-day in-hospital mortality and admission to intensive care unit (ICU), respectively. Cox regression (Fine-Gray model) was used to account for time-dependency and competing events, with inverse probability weighting to adjust for confounding., Results: We included 2901 patients with symptomatic healthcare-associated COVID-19 (Omicron) and 868 patients with symptomatic healthcare-associated influenza from nine hospitals. We found a similar case fatality ratio between healthcare-associated COVID-19 (Omicron) (6.2%) and healthcare-associated influenza (6.1%) patients; after adjustment, patients had a comparable subdistribution hazard ratio for 30-day in-hospital mortality (0.91, 95%CI 0.67-1.24). A similar proportion of patients were admitted to ICU (2.4% COVID-19; 2.6% influenza)., Conclusions: COVID-19 and influenza continue to cause severe disease among hospitalized patients. Our results suggest that in-hospital mortality risk of healthcare-associated COVID-19 (Omicron) and healthcare-associated influenza are comparable., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF
33. Swiss COVID-19 hospital surveillance: an in-depth analysis of the factors associated with hospital readmission dynamics in community-acquired COVID-19 cases.
- Author
-
Vancauwenberghe L, Roelens M, Urbini L, Iten A, Zanella MC, Nwosu K, Flury D, Buettcher M, Vuichard-Gysin D, Balmelli C, Tschudin-Sutter S, Schreiber PW, Troillet N, Sommerstein R, Jent P, Buchter V, Sobel J, Keiser O, and Estill J
- Subjects
- Humans, Switzerland epidemiology, Male, Female, Aged, Risk Factors, Middle Aged, Adult, Patient Discharge statistics & numerical data, Logistic Models, Aged, 80 and over, Patient Readmission statistics & numerical data, COVID-19 epidemiology, Community-Acquired Infections epidemiology, SARS-CoV-2
- Abstract
Background: The COVID-19 pandemic has placed unprecedented pressure on hospitals worldwide. In such a context of tension in healthcare systems, efficiently allocating hospital resources is a crucial aspect of crisis management. The aim of this study was to describe the clinical characteristics of readmitted patients and to determine risk factors for hospital readmission using data from the Swiss COVID-19 Hospital-Based Surveillance system (CH-SUR)., Methods: We investigated hospital readmissions within 60 days after discharge of patients from the CH-SUR surveillance system with a first hospitalisation between 1 December 2020 and 1 December 2021. Only community-acquired cases were considered. We compared the baseline characteristics of readmitted and non-readmitted patients. We performed univariable and multivariable logistic regression analyses to investigate the risk factors for hospital readmission., Findings: Of the 8039 eligible patients, 239 (3.0%, 95% confidence interval [CI] 2.6-3.3%) were readmitted to hospital within 60 days of discharge, with no significant variations observed over the study period; 80% of all readmissions occurred within 10 days of discharge of the index hospital stay. Based on our multivariable logistic regression models, factors increasing the odds of hospital readmission were age ≥65 years (odds ratio [OR] 1.63, 95% CI 1.24-2.15), male sex (OR 1.47, 95% CI 1.12-1.93), being discharged to home after first hospitalisation (OR 1.77, 95% CI 1.19-2.62), having oncological pathology (OR 1.82, 95% CI 1.27-2.61) and being immunosuppressed (OR 2.34, 95% CI 1.67-3.29)., Interpretations: Age, sex, cardiovascular diseases, oncological pathologies and immunosuppression were the main risk factors identified for hospital readmission.
- Published
- 2024
- Full Text
- View/download PDF
34. Povidone Iodine vs Chlorhexidine Gluconate in Alcohol for Preoperative Skin Antisepsis: A Randomized Clinical Trial.
- Author
-
Widmer AF, Atkinson A, Kuster SP, Wolfensberger A, Klimke S, Sommerstein R, Eckstein FS, Schoenhoff F, Beldi G, Gutschow CA, Marschall J, Schweiger A, and Jent P
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Abdomen surgery, Cardiac Surgical Procedures adverse effects, Cross-Over Studies, Skin microbiology, Adult, Incidence, Anti-Infective Agents, Local administration & dosage, Antisepsis methods, Chlorhexidine administration & dosage, Chlorhexidine analogs & derivatives, Ethanol administration & dosage, Povidone-Iodine administration & dosage, Preoperative Care methods, Surgical Wound Infection epidemiology, Surgical Wound Infection prevention & control
- Abstract
Importance: Preoperative skin antisepsis is an established procedure to prevent surgical site infections (SSIs). The choice of antiseptic agent, povidone iodine or chlorhexidine gluconate, remains debated., Objective: To determine whether povidone iodine in alcohol is noninferior to chlorhexidine gluconate in alcohol to prevent SSIs after cardiac or abdominal surgery., Design, Setting, and Participants: Multicenter, cluster-randomized, investigator-masked, crossover, noninferiority trial; 4403 patients undergoing cardiac or abdominal surgery in 3 tertiary care hospitals in Switzerland between September 2018 and March 2020 were assessed and 3360 patients were enrolled (cardiac, n = 2187 [65%]; abdominal, n = 1173 [35%]). The last follow-up was on July 1, 2020., Interventions: Over 18 consecutive months, study sites were randomly assigned each month to either use povidone iodine or chlorhexidine gluconate, each formulated in alcohol. Disinfectants and skin application processes were standardized and followed published protocols., Main Outcomes and Measures: Primary outcome was SSI within 30 days after abdominal surgery and within 1 year after cardiac surgery, using definitions from the US Centers for Disease Control and Prevention's National Healthcare Safety Network. A noninferiority margin of 2.5% was used. Secondary outcomes included SSIs stratified by depth of infection and type of surgery., Results: A total of 1598 patients (26 cluster periods) were randomly assigned to receive povidone iodine vs 1762 patients (26 cluster periods) to chlorhexidine gluconate. Mean (SD) age of patients was 65.0 years (39.0-79.0) in the povidone iodine group and 65.0 years (41.0-78.0) in the chlorhexidine gluconate group. Patients were 32.7% and 33.9% female in the povidone iodine and chlorhexidine gluconate groups, respectively. SSIs were identified in 80 patients (5.1%) in the povidone iodine group vs 97 (5.5%) in the chlorhexidine gluconate group, a difference of 0.4% (95% CI, -1.1% to 2.0%) with the lower limit of the CI not exceeding the predefined noninferiority margin of -2.5%; results were similar when corrected for clustering. The unadjusted relative risk for povidone iodine vs chlorhexidine gluconate was 0.92 (95% CI, 0.69-1.23). Nonsignificant differences were observed following stratification by type of surgical procedure. In cardiac surgery, SSIs were present in 4.2% of patients with povidone iodine vs 3.3% with chlorhexidine gluconate (relative risk, 1.26 [95% CI, 0.82-1.94]); in abdominal surgery, SSIs were present in 6.8% with povidone iodine vs 9.9% with chlorhexidine gluconate (relative risk, 0.69 [95% CI, 0.46-1.02])., Conclusions and Relevance: Povidone iodine in alcohol as preoperative skin antisepsis was noninferior to chlorhexidine gluconate in alcohol in preventing SSIs after cardiac or abdominal surgery., Trial Registration: ClinicalTrials.gov Identifier: NCT03685604.
- Published
- 2024
- Full Text
- View/download PDF
35. Hospital-acquired respiratory viral infections while applying droplet precautions on-site (DroPS) - prospective observation during the 2019/20 influenza season, Bern, Switzerland.
- Author
-
Birrer M, Draps K, Hobi F, Laguardia M, Hofmann E, Luginbühl M, Perrig M, Aujesky D, Marschall J, and Sommerstein R
- Abstract
Single room isolation for respiratory viral infections (RVI), like influenza, puts hospitals under pressure. During the influenza season 2019/20, we implemented Droplet precautions on-site (DroPS) for RVI in two acute care hospitals and prospectively assessed the rate of hospital-acquired RVI (HARVI). 318 patients were admitted with RVI, 85 had Influenza or RSV, 75 stayed in multi-bed rooms with DroPS. From 764 patients at risk , hospitalised ≥ three days in a multi-bed room , 11 (1.4%) developed a clinical HARVI, and three tested positive (3/764, 0.4%; 2x RSV, 1x influenza). DroPS may represent an alternative strategy to deal with respiratory viral infections., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
36. Association of institutional masking policies with healthcare-associated SARS-CoV-2 infections in Swiss acute care hospitals during the BA.4/5 wave (CH-SUR study): a retrospective observational study.
- Author
-
Dörr T, Güsewell S, Flury D, Süveges M, Gaza Valera CB, Botero-Mesa S, Zanella MC, Iten A, Balmelli C, Troillet N, Tschudin-Sutter S, W Schreiber P, Jent P, Damonti L, Sommerstein R, Portmann L, Vuichard-Gysin D, Cusini A, Nussbaumer-Ochsner Y, Heininger U, Berger C, Zimmermann P, Gardiol C, Keiser O, Schlegel M, Kohler P, and P Kuster S
- Subjects
- Humans, Switzerland epidemiology, Retrospective Studies, Female, Male, Middle Aged, Adult, Hospitals, Aged, Health Personnel, Infection Control methods, Organizational Policy, Aged, 80 and over, COVID-19 epidemiology, COVID-19 prevention & control, Masks, Cross Infection prevention & control, Cross Infection epidemiology, SARS-CoV-2
- Abstract
Background: In the initial phase of the SARS-CoV-2 pandemic, masking has been widely accepted in healthcare institutions to mitigate the risk of healthcare-associated infection. Evidence, however, is still scant and the role of masks in preventing healthcare-associated SARS-CoV-2 acquisition remains unclear.We investigated the association of variation in institutional mask policies with healthcare-associated SARS-CoV-2 infections in acute care hospitals in Switzerland during the BA.4/5 2022 wave., Methods: SARS-CoV-2 infections in hospitalized patients between June 1 and September 5, 2022, were obtained from the "Hospital-based surveillance of COVID-19 in Switzerland"-database and classified as healthcare- or community-associated based on time of disease onset. Institutions provided information regarding institutional masking policies for healthcare workers and other prevention policies. The percentage of healthcare-associated SARS-CoV-2 infections was calculated per institution and per type of mask policy. The association of healthcare-associated SARS-CoV-2 infections with mask policies was tested using a negative binominal mixed-effect model., Results: We included 2'980 SARS-CoV-2 infections from 13 institutions, 444 (15%) were classified as healthcare-associated. Between June 20 and June 30, 2022, six (46%) institutions switched to a more stringent mask policy. The percentage of healthcare-associated infections subsequently declined in institutions with policy switch but not in the others. In particular, the switch from situative masking (standard precautions) to general masking of HCW in contact with patients was followed by a strong reduction of healthcare-associated infections (rate ratio 0.39, 95% CI 0.30-0.49). In contrast, when compared across hospitals, the percentage of health-care associated infections was not related to mask policies., Conclusions: Our findings suggest switching to a more stringent mask policy may be beneficial during increases of healthcare-associated SARS-CoV-2 infections at an institutional level., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
37. Surgical Antimicrobial Prophylaxis in Low-Risk Cholecystectomies is Associated with Fewer Surgical Site Infections: Nationwide Cohort Study in Switzerland.
- Author
-
Florinett L, Widmer A, Troillet N, Beldi G, Von Flüe M, Harbarth S, and Sommerstein R
- Abstract
Objective: To assess whether administration of surgical antimicrobial prophylaxis (SAP) versus absence of SAP is associated with a decreased risk of surgical site infections (SSI) after low-risk cholecystectomies (LR-CCE)., Summary Background Data: Current guidelines do not recommend routine SAP administration prior to LR-CCE., Methods: This cohort study included adult patients who underwent LR-CCE and were documented by the Swissnoso SSI surveillance system between 1/2009-12/2020 at 66 Swiss hospitals. LR-CCE was specified as elective endoscopic surgery, age <70, no active cholecystitis, ASA score <3, operating time <120 minutes without implantation of foreign material. Exposure was defined as the administration of cefuroxime or cefazoline ± metronidazole within 120 minutes prior to incision versus no SAP administration. Our main outcome was occurrence of SSI until day 30. Logistic regression models were used to adjust for institutional, patient, and perioperative variables., Results: Of 44 682 surveilled adult cholecystectomy patients, 12 521 (8 726 women [69.7%]; median [IQR] age, 49.0 [38.1-58.2] years), fulfilled inclusion criteria. SSI was identified in 143 patients (1.1%). SAP was administered in 9 269 patients (74.0%) and was associated with a lower SSI rate (adjusted odds ratio [aOR], 0.50; 95% CI, 0.35-0.70; P < 0.001). The number needed to treat to prevent one SSI episode is 100., Conclusions: The overall LR-CCE SSI rate was 1.1%. SAP was associated with a 50% lower overall SSI rate. Patients undergoing LR-CCE may benefit from routine surgical antimicrobial prophylaxis., Competing Interests: Conflict of interest statement: RS received an unrestricted research grant from BBraun, Sempach, Switzerland., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Influence of patient characteristics on microbial composition in surgical-site infections: insights from national surveillance study.
- Author
-
Peisl S, Guillen-Ramirez H, Sánchez-Taltavull D, Widmer A, Sommerstein R, and Beldi G
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Switzerland epidemiology, Adult, Risk Factors, Age Factors, Body Mass Index, Antibiotic Prophylaxis, Operative Time, Surgical Wound Infection epidemiology, Surgical Wound Infection microbiology
- Abstract
Background: Although the impact of surgery- and patient-dependent factors on surgical-site infections (SSIs) have been studied extensively, their influence on the microbial composition of SSI remains unexplored. The aim of this study was to identify patient-dependent predictors of the microbial composition of SSIs across different types of surgery., Methods: This retrospective cohort study included 538 893 patients from the Swiss national infection surveillance programme. Multilabel classification methods, adaptive boosting and Gaussian Naive Bayes were employed to identify predictors of the microbial composition of SSIs using 20 features, including sex, age, BMI, duration of surgery, type of surgery, and surgical antimicrobial prophylaxis., Results: Overall, SSIs were recorded in 18 642 patients (3.8%) and, of these, 10 632 had microbiological wound swabs available. The most common pathogens identified in SSIs were Enterobacterales (57%), Staphylococcus spp. (31%), and Enterococcus spp. (28%). Age (mean feature importance 0.260, 95% c.i. 0.209 to 0.309), BMI (0.224, 0.177 to 0.271), and duration of surgery (0.221, 0.180 to 0.269) were strong and independent predictors of the microbial composition of SSIs. Increasing age and duration of surgical procedure as well as decreasing BMI were associated with a shift from Staphylococcus spp. to Enterobacterales and Enterococcus spp. An online application of the machine learning model is available for validation in other healthcare systems., Conclusion: Age, BMI, and duration of surgery were key predictors of the microbial composition of SSI, irrespective of the type of surgery, demonstrating the relevance of patient-dependent factors to the pathogenesis of SSIs., (© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
39. Association of a coronavirus disease 2019 (COVID-19) vaccine booster with control of a COVID-19 outbreak in a long-term care facility in Switzerland, November to December 2021.
- Author
-
Leiblein TW, Winistörfer A, Seiler K, Hauri R, and Sommerstein R
- Subjects
- Humans, Switzerland epidemiology, Long-Term Care, Nursing Homes, Disease Outbreaks prevention & control, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
Coronavirus disease 2019 (COVID-19) outbreaks in long-term care facilities are often correlated with high case fatality rates. We describe the association of administration of an mRNA booster with the control of an outbreak. Our findings highlight the possibility of vaccine booster early in an outbreak as a promising method to mitigate the spread of infection.
- Published
- 2024
- Full Text
- View/download PDF
40. Association between the introduction of a national targeted intervention program and the incidence of surgical site infections in Swiss acute care hospitals.
- Author
-
Eder M, Sommerstein R, Szelecsenyi A, Schweiger A, Schlegel M, Atkinson A, Kuster SP, Vuichard-Gysin D, Troillet N, and Widmer AF
- Subjects
- Female, Humans, Incidence, Prospective Studies, Switzerland epidemiology, Adult, Aged, Middle Aged, Hospitals, Surgical Wound Infection epidemiology, Surgical Wound Infection prevention & control, Surgical Wound Infection drug therapy
- Abstract
Background: In Switzerland, the national surgical site infection (SSI) surveillance program showed a modest decrease in SSI rates for different procedures over the last decade. The study aimed to determine whether a multimodal, targeted intervention program in addition to existing SSI surveillance is associated with decreased SSI rates in the participating hospitals., Methods: Prospective multicenter pre- and postintervention study conducted in eight Swiss acute care hospitals between 2013 and 2020. All consecutive patients > 18 years undergoing cardiac, colon, or hip/knee replacement surgery were included. The follow-up period was 30 days and one year for implant-related surgery. Patients with at least one follow-up were included. The intervention was to optimize three elements of preoperative management: (i) hair removal; (ii) skin disinfection; and (iii) perioperative antimicrobial prophylaxis. We compared SSI incidence rates (main outcome measure) pre- and postintervention (three years each) adjusted for potential confounders. Poisson generalized linear mixed models fitted to quarter-yearly confirmed SSIs and adjusted for baseline differences between hospitals and procedures. Adherence was routinely monitored through on-site visits., Results: A total of 10 151 patients were included, with a similar median age pre- and postintervention (69.6 and IQR 60.9, 76.8 years, vs 69.5 and IQR 60.4, 76.8 years, respectively; P = 0.55) and similar proportions of females (44.8% vs. 46.1%, respectively; P = 0.227). Preintervention, 309 SSIs occurred in 5 489 patients (5.6%), compared to 226 infections in 4 662 cases (4.8%, P = 0.09) postintervention. The adjusted incidence rate ratio (aIRR) for overall SSI after intervention implementation was 0.81 (95% CI, 0.68 to 0.96, P = 0.02). For cardiac surgery (n = 2 927), the aIRR of SSI was 0.48 (95% CI, 0.32 to 0.72, P < 0.001). For hip/knee replacement surgery (n = 4 522), the aIRR was 0.88 (95% CI, 0.52 to 1.48, P = 0.63), and for colon surgery (n = 2 702), the aIRR was 0.92 (95% CI, 0.75 to 1.14, P = 0.49)., Conclusions: The SSI intervention bundle was associated with a statistically significant decrease in SSI cases. A significant association was observed for cardiac surgery. Adding a specific intervention program can add value compared to routine surveillance only. Further prevention modules might be necessary for colon and orthopedic surgery., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
41. [Surgical site infection after lower limb arterial reconstruction: can we improve prevention?]
- Author
-
Catho G, Moulin E, Sommerstein R, Deslarzes C, Arts L, Danzer D, Haller C, and Berthod D
- Subjects
- Humans, Staphylococcus aureus, Anti-Bacterial Agents therapeutic use, Antibiotic Prophylaxis adverse effects, Vascular Surgical Procedures adverse effects, Surgical Wound Infection epidemiology, Surgical Wound Infection prevention & control, Surgical Wound Infection drug therapy, Staphylococcal Infections drug therapy
- Abstract
Infections associated with arterial reconstructions of the lower limbs are associated with high morbidity. This article reviews the risk factors for infection associated with this surgery and the preventive measures. These include smoking cessation and glycemic control preoperatively; avoiding unnecessary exposure to antibiotics or corticosteroids; optimal peripheral wound care; rigorous antisepsis and antibiotic prophylaxis in the operating theatre ; and finally, meticulous post-operative wound monitoring. The benefit of Staphylococcus aureus decolonization in vascular surgery is less clearly established than in cardiac and thoracic surgery, but it is still recommended in cases of implant placement or where there is a high risk of S. aureus infection, depending on the planned approach and type of surgery., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article
- Published
- 2023
- Full Text
- View/download PDF
42. Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis.
- Author
-
Estill J, Venkova-Marchevska P, Günthard HF, Botero-Mesa S, Thiabaud A, Roelens M, Vancauwenberghe L, Damonti L, Heininger U, Iten A, Schreiber PW, Sommerstein R, Tschudin-Sutter S, Troillet N, Vuichard-Gysin D, Widmer A, Hothorn T, and Keiser O
- Subjects
- Aged, Male, Humans, Switzerland epidemiology, COVID-19 Drug Treatment, Hospitals, Antiviral Agents therapeutic use, COVID-19
- Abstract
Aims of the Study: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by patient characteristics., Methods: We analysed data collected from a hospital surveillance study conducted in 21 referral hospitals in Switzerland between 2020 and 2022. We applied model-based recursive partitioning to group patients by the association between treatment levels and mortality. We included either treatment (levels: none, remdesivir within 7 days of symptom onset, remdesivir after 7 days, or another treatment), age and sex, or treatment only as regression variables. Candidate partitioning variables included a range of risk factors and comorbidities (and age and sex unless included in regression). We repeated the analyses using local centring to correct the results for the propensity to receive treatment., Results: Overall (n = 21,790 patients), remdesivir within 7 days was associated with increased mortality (adjusted hazard ratios 1.28-1.54 versus no treatment). The CURB-65 score caused the most instability in the regression parameters of the model. When adjusted for age and sex, patients receiving remdesivir within 7 days of onset had higher mortality than those not treated in all identified eight patient groups. When age and sex were included as partitioning variables instead, the number of groups increased to 19-20; in five to six of those branches, mortality was lower among patients who received early remdesivir. Factors determining the groups where remdesivir was potentially beneficial included the presence of oncological comorbidities, male sex, and high age., Conclusions: Some subgroups of patients, such as individuals with oncological comorbidities or elderly males, may benefit from remdesivir.
- Published
- 2023
- Full Text
- View/download PDF
43. Timing of Cefuroxime Surgical Antimicrobial Prophylaxis and Its Association With Surgical Site Infections.
- Author
-
Sommerstein R, Troillet N, Harbarth S, de Kraker MEA, Vuichard-Gysin D, Kuster SP, and Widmer AF
- Subjects
- United States, Male, Adult, Humans, Aged, Surgical Wound Infection epidemiology, Surgical Wound Infection prevention & control, Surgical Wound Infection drug therapy, Anti-Bacterial Agents therapeutic use, Cohort Studies, Antibiotic Prophylaxis methods, Risk Factors, Time Factors, Cefuroxime therapeutic use, Anti-Infective Agents therapeutic use
- Abstract
Importance: World Health Organization guidelines recommend administering surgical antimicrobial prophylaxis (SAP), including cefuroxime, within 120 minutes prior to incision. However, data from clinical settings supporting this long interval is limited., Objective: To assess whether earlier vs later timing of administration of cefuroxime SAP is associated with the occurrence of surgical site infections (SSI)., Design, Setting, and Participants: This cohort study included adult patients who underwent 1 of 11 major surgical procedures with cefuroxime SAP, documented by the Swissnoso SSI surveillance system between January 2009 and December 2020 at 158 Swiss hospitals. Data were analyzed from January 2021 to April 2023., Exposures: Timing of cefuroxime SAP administration before incision was divided into 3 groups: 61 to 120 minutes before incision, 31 to 60 minutes before incision, and 0 to 30 minutes before incision. In addition, a subgroup analysis was performed with time windows of 30 to 55 minutes and 10 to 25 minutes as a surrogate marker for administration in the preoperating room vs in the operating room, respectively. The timing of SAP administration was defined as the start of the infusion obtained from the anesthesia protocol., Main Outcomes and Measures: Occurrence of SSI according to Centers for Disease Control and Prevention definitions. Mixed-effects logistic regression models adjusted for institutional, patient, and perioperative variables were applied., Results: Of 538 967 surveilled patients, 222 439 (104 047 men [46.8%]; median [IQR] age, 65.7 [53.9-74.2] years), fulfilled inclusion criteria. SSI was identified in 5355 patients (2.4%). Cefuroxime SAP was administered 61 to 120 minutes prior to incision in 27 207 patients (12.2%), 31 to 60 minutes prior to incision in 118 004 patients (53.1%), and 0 to 30 minutes prior to incision in 77 228 patients (34.7%). SAP administration at 0 to 30 minutes was significantly associated with a lower SSI rate (adjusted odds ratio [aOR], 0.85; 95% CI, 0.78-0.93; P < .001), as was SAP administration 31 to 60 minutes prior to incision (aOR, 0.91; 95% CI, 0.84-0.98; P = .01) compared with administration 61 to 120 minutes prior to incision. Administration 10 to 25 minutes prior to incision in 45 448 patients (20.4%) was significantly associated with a lower SSI rate (aOR, 0.89; 95% CI, 0.82-0.97; P = .009) vs administration within 30 to 55 minutes prior to incision in 117 348 patients (52.8%)., Conclusions and Relevance: In this cohort study, administration of cefuroxime SAP closer to the incision time was associated with significantly lower odds of SSI, suggesting that cefuroxime SAP should be administrated within 60 minutes prior to incision, and ideally within 10 to 25 minutes.
- Published
- 2023
- Full Text
- View/download PDF
44. Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland.
- Author
-
Portmann L, de Kraker MEA, Fröhlich G, Thiabaud A, Roelens M, Schreiber PW, Troillet N, Iten A, Widmer A, Harbarth S, and Sommerstein R
- Subjects
- Humans, Female, Aged, Male, Cohort Studies, Hospital Mortality, Pandemics, Prospective Studies, SARS-CoV-2, Switzerland epidemiology, Hospitals, Influenza, Human epidemiology, COVID-19 epidemiology, Community-Acquired Infections epidemiology
- Abstract
Importance: With the ongoing COVID-19 pandemic, it is crucial to assess the current burden of disease of community-acquired SARS-CoV-2 Omicron variant in hospitalized patients to tailor appropriate public health policies. Comparisons with better-known seasonal influenza infections may facilitate such decisions., Objective: To compare the in-hospital outcomes of patients hospitalized with the SARS-CoV-2 Omicron variant with patients with influenza., Design, Setting, and Participants: This cohort study was based on a national COVID-19 and influenza registry. Hospitalized patients aged 18 years and older with community-acquired SARS-CoV-2 Omicron variant infection who were admitted between January 15 and March 15, 2022 (when B.1.1.529 Omicron predominance was >95%), and hospitalized patients with influenza A or B infection from January 1, 2018, to March 15, 2022, where included. Patients without a study outcome by August 30, 2022, were censored. The study was conducted at 15 hospitals in Switzerland., Exposures: Community-acquired SARS-CoV-2 Omicron variant vs community-acquired seasonal influenza A or B., Main Outcomes and Measures: Primary and secondary outcomes were defined as in-hospital mortality and admission to the intensive care unit (ICU) for patients with the SARS-CoV-2 Omicron variant or influenza. Cox regression (cause-specific and Fine-Gray subdistribution hazard models) was used to account for time-dependency and competing events, with inverse probability weighting to adjust for confounders with right-censoring at day 30., Results: Of 5212 patients included from 15 hospitals, 3066 (58.8%) had SARS-CoV-2 Omicron variant infection in 14 centers and 2146 patients (41.2%) had influenza A or B in 14 centers. Of patients with the SARS-CoV-2 Omicron variant, 1485 (48.4%) were female, while 1113 patients with influenza (51.9%) were female (P = .02). Patients with the SARS-CoV-2 Omicron variant were younger (median [IQR] age, 71 [53-82] years) than those with influenza (median [IQR] age, 74 [59-83] years; P < .001). Overall, 214 patients with the SARS-CoV-2 Omicron variant (7.0%) died during hospitalization vs 95 patients with influenza (4.4%; P < .001). The final adjusted subdistribution hazard ratio (sdHR) for in-hospital death for SARS-CoV-2 Omicron variant vs influenza was 1.54 (95% CI, 1.18-2.01; P = .002). Overall, 250 patients with the SARS-CoV-2 Omicron variant (8.6%) vs 169 patients with influenza (8.3%) were admitted to the ICU (P = .79). After adjustment, the SARS-CoV-2 Omicron variant was not significantly associated with increased ICU admission vs influenza (sdHR, 1.08; 95% CI, 0.88-1.32; P = .50)., Conclusions and Relevance: The data from this prospective, multicenter cohort study suggest a significantly increased risk of in-hospital mortality for patients with the SARS-CoV-2 Omicron variant vs those with influenza, while ICU admission rates were similar.
- Published
- 2023
- Full Text
- View/download PDF
45. Nosocomial outbreak of vancomycin-resistant Enterococcus faecium (VRE) ST796, Switzerland, 2017 to 2020.
- Author
-
Piezzi V, Wassilew N, Atkinson A, D'Incau S, Kaspar T, Seth-Smith HM, Casanova C, Bittel P, Jent P, Sommerstein R, Buetti N, and Marschall J
- Subjects
- Humans, Vancomycin, Switzerland epidemiology, Disease Outbreaks, Hospitals, University, Enterococcus faecium genetics, Cross Infection epidemiology, Vancomycin-Resistant Enterococci genetics, Gram-Positive Bacterial Infections epidemiology
- Abstract
A large clonal outbreak caused by vancomycin-resistant Enterococcus faecium (VRE) affected the Bern University Hospital group from the end of December 2017 until July 2020. We describe the characteristics of the outbreak and the bundle of infection prevention and control (IPC) measures implemented. The outbreak was first recognised when two concomitant cases of VRE bloodstream infection were identified on the oncology ward. During 32 months, 518 patients in the 1,300-bed hospital group were identified as vanB VRE carriers. Eighteen (3.5%) patients developed an invasive infection, of whom seven had bacteraemia. In 2018, a subset of 328 isolates were analysed by whole genome sequencing, 312 of which were identified as sequence type (ST) 796. The initial IPC measures were implemented with a focus on the affected wards. However, in June 2018, ST796 caused another increase in cases, and the management strategy was intensified and escalated to a hospital-wide level. The clinical impact of this large nosocomial VRE outbreak with the emergent clone ST796 was modest. A hospital-wide approach with a multimodal IPC bundle was successful against this highly transmissible strain.
- Published
- 2022
- Full Text
- View/download PDF
46. The impact of public health interventions on the future prevalence of ESBL-producing Klebsiella pneumoniae: a population based mathematical modelling study.
- Author
-
Salazar-Vizcaya L, Atkinson A, Kronenberg A, Plüss-Suard C, Kouyos RD, Kachalov V, Troillet N, Marschall J, and Sommerstein R
- Subjects
- Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Escherichia coli, Humans, Klebsiella pneumoniae, Microbial Sensitivity Tests, Models, Theoretical, Prevalence, Public Health, beta-Lactamases genetics, Escherichia coli Infections microbiology, Klebsiella Infections epidemiology, Klebsiella Infections microbiology, Klebsiella Infections prevention & control
- Abstract
Background: Future prevalence of colonization with extended-spectrum betalactamase (ESBL-) producing K. pneumoniae in humans and the potential of public health interventions against the spread of these resistant bacteria remain uncertain., Methods: Based on antimicrobial consumption and susceptibility data recorded during > 13 years in a Swiss region, we developed a mathematical model to assess the comparative effect of different interventions on the prevalence of colonization., Results: Simulated prevalence stabilized in the near future when rates of antimicrobial consumption and in-hospital transmission were assumed to remain stable (2025 prevalence: 6.8% (95CI%:5.4-8.8%) in hospitals, 3.5% (2.5-5.0%) in the community versus 6.1% (5.0-7.5%) and 3.2% (2.3-4.2%) in 2019, respectively). When overall antimicrobial consumption was set to decrease by 50%, 2025 prevalence declined by 75% in hospitals and by 64% in the community. A 50% decline in in-hospital transmission rate led to a reduction in 2025 prevalence of 31% in hospitals and no reduction in the community. The best model fit estimated that 49% (6-100%) of observed colonizations could be attributable to sources other than human-to-human transmission within the geographical setting., Conclusions: Projections suggests that overall antimicrobial consumption will be, by far, the most powerful driver of prevalence and that a large fraction of colonizations could be attributed to non-local transmissions., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
47. Agrobacterium species bacteraemia, Switzerland, 2008 to 2019: a molecular epidemiological study.
- Author
-
Balmer L, Seth-Smith HMB, Egli A, Casanova C, Kronenberg A, Schrenzel J, Marschall J, and Sommerstein R
- Subjects
- Humans, Prospective Studies, Retrospective Studies, Switzerland epidemiology, Agrobacterium, Bacteremia epidemiology
- Abstract
Background: Agrobacterium spp. are infrequent agents of bloodstream infections linked to healthcare-associated outbreaks. However, it is unclear if outbreaks also occur across larger geographic areas. Triggered by two local clusters from putative point sources, our aim was to detect potential additional clusters in Switzerland., Methods: We performed a nationwide descriptive study of cases in Switzerland based on a prospective surveillance system (Swiss Centre for Antibiotic Resistance, anresis.ch), from 2008 to 2019. We identified patients with Agrobacterium spp. isolated from blood cultures and used a survey to collect clinical-epidemiological information and susceptibility testing results. We performed whole genome sequencing (WGS) of available clinical isolates and determined their relatedness by single nucleotide polymorphism (SNP) variant calling analysis., Results: We identified a total of 36 cases of Agrobacterium spp. from blood samples over 10 years. Beyond previously known local clusters, no new ones were identified. WGS-based typing was performed on 22 available isolates and showed no clonal relationships between newly identified isolates or to those from the known clusters, with all isolates outside these clusters being at least 50 SNPs apart., Conclusion and Relevance: Agrobacterium spp. bacteraemia is infrequently detected and, given that it may be healthcare-associated and stem from a point source, occurrence of multiple episodes should entail an outbreak investigation. With the help of the national antimicrobial resistance surveillance system we identified multiple clinical cases of this rare pathogen but found no evidence by WGS that suggested a nation-wide outbreak., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
48. Meticillin-resistant Staphylococcus aureus Contact Screening Strategy in a Low Prevalence Setting; a Nested Case-Control Study.
- Author
-
Bächli M, Sommerstein R, Casanova C, Droz S, Küffer M, and Marschall J
- Abstract
Background: The optimal screening strategy in hospitals to identify secondary cases after contact with a meticillin-resistant Staphylococcus aureus (MRSA) index patient in a low prevalence setting is not well defined. We aimed at identifying factors associated with documented MRSA transmissions., Method: Single center, retrospective, nested case-control study. We evaluated the screening strategy in our 950 bed tertiary care hospital from 2008 - 2014. Room and ward contacts of MRSA index patients present at time of MRSA identification were screened. We compared characteristics of Staphylococcus aureus Protein A (spa)-type matched contact patients (cases) to negative or spa-type mismatched contact patients (controls)., Results: Among 270,000 inpatients from 2008 - 2014, 215 MRSA screenings yielded 3013 contact patients, and 6 (0.2%) spa-type matched pairs. We included 225 controls for the nested case-control study. The contact type for the cases was more frequently "same room" and less frequently "same ward" compared with the controls ( P = 0.001). Also, exposure time was longer for cases (median of 6 days [IQR 3-9]) than for controls (1 day [0-3], P =0.016)., Conclusion: The extensive MRSA screening strategy revealed only few index/contact matches based on spa-typing. Prolonged exposure time and a shared room were significantly associated with MRSA transmission. A targeted screening strategy may be more useful in a low prevalence setting than screening entire wards., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
49. Providing care to patients in contact isolation: is the systematic use of gloves still indicated?
- Author
-
Bellini C, Eder M, Senn L, Sommerstein R, Vuichard-Gysin D, Schmiedel Y, Schlegel M, Harbarth S, and Troillet N
- Subjects
- Gloves, Protective, Guideline Adherence, Health Personnel, Humans, Infection Control, Cross Infection prevention & control, Hand Hygiene
- Abstract
This article reviews the available evidence on the effectiveness of gloves in preventing infection during care provided to patients under contact precautions, and analyses the risks and benefits of their systematic use. Although hand hygiene with alcohol-based handrub was shown to be effective in preventing nosocomial infections, many publications put the effectiveness and usefulness of gloves into perspective. Instead, literature and various unpublished experiences point towards reduced hand hygiene compliance and increased risk of spreading pathogens with routine glove use. Therefore, hospitals should emphasise hand hygiene in their healthcare staff and, instead of the routine use of gloves when caring for patients under contact precautions, limit their use to the indications of standard precautions, i.e., mainly for contact with body fluids. Wide and easy access to alcohol-based handrub and continual teaching are essential. If such conditions are met and adherence to hand hygiene is excellent and regularly assessed, the routine use of gloves for patients under contact precautions seems no longer indicated.
- Published
- 2022
- Full Text
- View/download PDF
50. High adherence to national IPC guidelines as key to sustainable VRE control in Swiss hospitals: a cross-sectional survey.
- Author
-
Vuichard-Gysin D, Sommerstein R, Kronenberg A, Buetti N, Eder M, Piezzi V, Gardiol C, Schlegel M, Harbarth S, and Widmer A
- Subjects
- Cross-Sectional Studies, Humans, Switzerland, Cross Infection prevention & control, Gram-Positive Bacterial Infections prevention & control, Hospitals, Infection Control statistics & numerical data, Vancomycin Resistance, Vancomycin-Resistant Enterococci physiology
- Abstract
Background: Vancomycin resistant enterococci (VRE) are on the rise in many European hospitals. In 2018, Switzerland experienced its largest nosocomial VRE outbreak. The national center for infection prevention (Swissnoso) elaborated recommendations for controlling this outbreak and published guidelines to prevent epidemic and endemic VRE spread. The primary goal of this study was to evaluate adherence to this new guideline and its potential impact on the VRE epidemiology in Swiss acute care hospitals., Methods: In March 2020, Swissnoso distributed a survey among all Swiss acute care hospitals. The level of adherence as well as changes of infection prevention and control (IPC) strategies in the years 2018 and 2019 after publication of the national guidelines were asked along with an inventory on VRE surveillance and outbreaks., Results: Data of 97/146 (66%) participants were available, representing 81.6% of all acute care beds operated in Switzerland in 2019. The vast majority-72/81 (88%) responding hospitals-have entirely or largely adopted our new national guideline. 38/51 (74.5%) hospitals which experienced VRE cases were significantly more likely to have changed their IPC strategies than those 19/38 (50%) hospitals without VRE cases p = 0.017). The new IPC guidelines included (1) introduction of targeted admission screening in 89.5%, (2) screening of close contacts of VRE cases in 56%, and (3) contact precaution for suspected VRE cases 58% of these hospitals. 52 (54%) hospitals reported 569 new VRE cases in 2018 including 14 bacteremia, and 472 new cases in 2019 with 10 bacteremia. The ten largest outbreaks encountered between 2018 and 2019 included 671 VRE cases, of which most (93.4%) consisted of colonization events, 29 (4.3%) infections and 15 (2.2%) bacteremia., Conclusion: Wide adoption of this VRE control guideline seemed to have a positive effect on VRE containment in Swiss acute care hospitals over two years, even if its long-term impact on the VRE epidemiology remains to be evaluated. Broad dissemination and strict implementation of a uniform national guideline may therefore serve as model for other countries to fight VRE epidemics on a national level., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.